IKS2024-10-012024-12-31 IKS2024-10-012024-12-31 IKS2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member IKS2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member IKS2024-12-31 IKS2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IKS2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member IKS2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IKS2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member IKS2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member IKS2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member IKS2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member IKS2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544309 IKS NOTLISTED Inventurus Knowledge Solutions Limited Equity 2024-04-01 2025-03-31 2025-02-05 2025-01-16 INR Millions Third quarter 19:30:00 20:43:00 2025-02-05 2025-02-05 Not applicable Single segment CARE ENABLEMENT PLATFORM PROVIDING TECHNOLOGY ENABLED SOLUTIONS TO HEALTHCARE PROVIDERS 2024-10-01 2024-12-31 Unaudited Consolidated 6571610000.00 269890000.00 6841500000.00 0.00 0.00 0.00 3833740000.00 205400000.00 277570000.00 923240000.00 5239950000.00 1601550000.00 0.00 1601550000.00 365481000.00 -60681000.00 304800000.00 0.00 1296750000.00 0.00 0.00 0.00 0.00 1296750000.00 47260000.00 1344010000.00 0.00 0.00 169770000.00 1 7.80 7.60 0.00 0.00 7.80 7.60 Notes : 1.The above standalone financial results of Inventurus Knowledge Solutions Limited ( the Company ) and consolidated financial results of the Company and its subsidiaries (collectively the Group ) for the quarter and nine months ended December 31,2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on February 5, 2025. The above results for the quarter and nine months ended December 31, 2024 have been reviewed by the Statutory Auditors of the Company in terms of Regulation 33 of the SEBl (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The figures for the quarter ended September 30,2024, corresponding quarter ended December 31,2023 and corresponding nine months ended December 31,2023 as reported in the statement have been approved by the Company's Board of Directors but have not been subjected to limited review since the requirement of submission of quarterly consolidated financial results is applicable on listing of equity shares of the Company from the quarter ended December 31,2024. 2.This statement has been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards( Ind AS ) as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder. 3.The Group operates in one reportable business segment which comprises a Care enablement platform providing technology enabled solutions to Healthcare providers. This in the context of Indian Accounting Standard (Ind AS 108) Operating Segments , constitutes a single operating segment. 4.During the quarter and nine months ended December 31, 2024, the Company has allotted 36,100 shares (previous period 485,000 shares) for the quarter and 183,202 shares ( previous period 729,400 shares) for the nine months ended December 31, 2024 respectively on exercise of Employee Stock options. Accordingly, the Company has transferred Rs. 14.18 million to the Securities Premium during the nine months ended December 31, 2024. 5. The Board at their meeting held on April 22, 2022 approved the 2022 Plan, for issue of shares / options to key employees of the Company and its subsidiaries. During the quarter and nine months ended December 31, 2024, the Company has granted 2,903,600 and 3,699,840 stock options respectively to eligible employees, as approved in the Nomination and Remuneration Committee meeting. The related share based compensation expense for the quarter and nine months ended December 31, 2024 is Rs. 64.40 million and Rs. 161.11 million respectively. 6.Earnings per share for the interim periods are not annualised. 7.The consolidated financial results of the Group for the quarter and nine months ended December 31, 2024, include the results of its subsidiary companies viz: Inventurus Knowledge Solutions Inc, IKS Cares Foundation and its step down subsidiary companies viz: Aquity Holdings Inc, Aquity Solutions LLC, Aquity Solutions India Private Limited, Aquity Solutions Australia Pty Limited, Aquity Canada ULC. 8.The figures appearing in the quarter and nine months ended December 31, 2023 of the consolidated financial results includes figures of Aquity Holdings Inc acquired on October 27, 2023, and hence are not comparable with the other periods presented above. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 19400380000.00 387230000.00 19787610000.00 0.00 0.00 7470000.00 11080560000.00 687460000.00 843300000.00 2906850000.00 15525640000.00 4261970000.00 0.00 4261970000.00 1083580000.00 -204190000.00 879390000.00 0.00 3382580000.00 0.00 0.00 0.00 0.00 3382580000.00 51860000.00 3434440000.00 0.00 0.00 169770000.00 1 20.35 19.84 0.00 0.00 20.35 19.84 Other Expenses 923240000.00 Other Expenses 2906850000.00 Not Applicable, refere note3. of the Statement of unaudited financial results for the quarter and nine months ended December 31, 2024. Remeasurement of post employment benefit obligations 2210000.00 Changes in the fair value of equity investments at FVOCI 0.00 Remeasurement of post employment benefit obligations -15710000.00 Changes in the fair value of equity investments at FVOCI 2050000.00 2210000.00 -13660000.00 400000.00 -2030000.00 Gains/ (losses) on cash flow hedges (net) -198020000.00 Exchange differences on translation of financial statements of foreign operations 211880000.00 Gains/ (losses) on cash flow hedges (net) -219350000.00 Exchange differences on translation of financial statements of foreign operations 248190000.00 13860000.00 28840000.00 -31590000.00 -34650000.00